Merck schedules pivotal ESMO data. Merck & Co. stock falls 1.16 percent

Published on 10/19/2026 at 09:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck brings 3 Phase 3 datasets to ESMO on October 26, 2026. Merck & Co. stock costs EUR 129.03 October 19, 2026, below Xetra's EUR 130.54 close.

Pipeline data and valuation

Merck announced three first-time Phase 3 oncology readouts for ESMO on October 15, 2026.
Second-quarter 2026 revenue reached USD 16.61 billion, up 5.10 percent year over year.
Merck & Co. stock trades at EUR 129.03 at 9:51 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.16 percent below the Xetra close of October 16, 2026.
RBC cut its target from USD 150.00 to USD 145.00 on October 12, 2026.

Black and white documentary photograph of a scientist in protective gloves and mask working inside a laminar flow biosafety cabinet. Precise hands pipette cell culture medium into multi-well plates. CO2 incubators line the background in dramatic side-lit — Merck US58933Y1055 Zellkultur schwarzweiß: Forscherin pipettiert konzentriert in steriler Biosicherheitswerkbank, dokumentarische Reportage, Illustration mit AI erstellt.

Merck & Co. (US58933Y1055) was trading at EUR 129.03 at Lang & Schwarz on October 19, 2026 at 9:51 a.m. CEST, down 1.16 percent versus the Xetra close of October 16, 2026 at EUR 130.54. The company is preparing investors for three first-time Phase 3 oncology readouts at the European Society for Medical Oncology congress, as Merck reported on October 15, 2026.

Pipeline data takes center stage

Merck said the ESMO program will include first presentations from the INTerpath-001, TroFuse-005 and KEYNOTE-C93 studies. The company also plans to present more than 90 additional abstracts covering more than 20 tumor types, according to Merck.com on October 15, 2026.

The October 26 investor event gives management a separate opportunity to explain how the pipeline can broaden growth beyond Keytruda. That matters because the company is balancing established oncology revenue with newer product launches and longer-term patent exposure.

What does the earnings base show?

Merck reported second-quarter 2026 revenue of USD 16.61 billion, up 5.10 percent from the prior-year quarter and above the USD 16.37 billion consensus cited by MarketBeat. The comparison makes the next report important: investors will judge whether launch growth can offset pressure on mature medicines.

Three dates define the setup

On August 4, 2026, Merck reported second-quarter revenue of USD 16.61 billion; on October 14, 2026, it inaugurated a USD 550 million bioanalytical facility; and on October 15, 2026, it outlined three Phase 3 oncology presentations, according to Merck and Merck.com.

Upcoming dates for investors

Merck's next two dated events are the oncology investor event on October 26, 2026 and the third-quarter 2026 earnings call on October 29, 2026, which the company announced through Business Wire.

Analyst caution contrasts with pipeline hopes

RBC Capital lowered its price target from USD 150.00 to USD 145.00 on October 12, 2026 and kept a Sector Perform rating, as reported by Markets Insider. The target change puts the upcoming oncology data in a demanding valuation context.

Stock valuation and trading context

Merck's NYSE stock closed at USD 145.95 on October 16, 2026, while its 52-week range was USD 82.01 to USD 156.92. Its market capitalization was USD 360.1 billion on October 19, 2026. At Lang & Schwarz, the euro indication was EUR 129.03 on October 19, 2026 at 9:51 a.m. CEST, 1.16 percent below the Xetra close of October 16, 2026 at EUR 130.54. The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.